Alzheimer's drug trial shown to slow cognitive decline in long fight against dementia

Hope against Alzheimer's: a new drug managed to slow cognitive development

This was demonstrated by a study among 1,800 patients published in the New England Journal of Medicine. Laboratories will request authorization from the FDA and the EMA.

Alzheimer's Drug From Eisai and Biogen Slows Cognitive Decline, Side-Effects in Focus

SAN FRANCISCO—An experimental Alzheimer’s drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of serious side effects for certain patients, according to detailed data presented on Tuesday. The drug, lecanemab, was associated with a dangerous type of brain swelling in nearly 13 percent of patients in the trial that spanned 18 months and enrolled nearly 1,800 participants with early-stage Alzheimer’s…

New Alzheimer’s drug slows cognitive decline, experts say

For the first time, a new medication has made a breakthrough by appearing to slow down the progression of Alzheimer's, researchers say.

New Alzheimer’s drug slows progression slightly, study results show

An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening — but the anxiously awaited new data leaves unclear how much difference that might make in people’s lives.

New Alzheimer’s drug can slow cognitive decline

ST. LOUIS COUNTY, Mo. - A new drug can slow the effects of Alzheimer's, according to a report published Tuesday in The New England Journal of Medicine. Lecanemab is one of the first experimental dementia drugs to appear to slow the progression of cognitive decline. For patients in the early stages of Alzheimer's, the drug slowed the rate of cognitive decline by 27%. Trending: Eye-popping mansion rests on 230-acre estate in Carbondale, Illin…

Drug shows promise in reducing brain decline in Alzheimer's patients

A breakthrough may be on the horizon for some who suffer from Alzheimer's disease after researchers said trial data shows a new drug slowed the rate of cognitive decline in patients.